Is propranolol (a beta blocker) contraindicated with tadalafil (a phosphodiesterase type 5 inhibitor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Propranolol is not contraindicated with tadalafil, but caution should be exercised when using these medications together. The 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease 1 does not explicitly mention a contraindication between propranolol and tadalafil. However, it does highlight the potential for severe hypotension when phosphodiesterase type 5 inhibitors, such as tadalafil, are used concomitantly with nitrate medications. Although propranolol is not a nitrate, its beta-blocking effects can lower blood pressure, and the combined use with tadalafil may potentially cause additive hypotensive effects.

When considering the use of propranolol and tadalafil together, it is essential to weigh the benefits against the potential risks. The guideline suggests that patients on long-acting nitrate therapy who want to use a phosphodiesterase type 5 inhibitor should have their treatment guided by the need for continued nitrate therapy versus other alternative options available to the treating clinician 1. Similarly, patients taking propranolol and tadalafil should be monitored for symptoms of low blood pressure, such as dizziness, lightheadedness, or fainting, especially when initiating therapy or adjusting doses.

Key considerations when using propranolol and tadalafil together include:

  • Monitoring for symptoms of low blood pressure
  • Maintaining adequate hydration
  • Avoiding excessive alcohol consumption
  • Regularly reviewing and adjusting medication doses as needed
  • Ensuring patients with cardiovascular disease are particularly cautious and discuss this combination with their healthcare provider to ensure appropriate monitoring and dosing.

From the Research

Contraindications and Precautions

  • The use of tadalafil with any nitric oxide donor is contraindicated due to the risk of significant arterial hypotension 2, 3, 4.
  • Caution is needed when using tadalafil with alpha-blocking agents, as this combination may lead to larger declines in blood pressure and cause orthostatic hypotension 2, 3, 4.
  • The concomitant use of tadalafil with beta blockers, such as propranolol, is not explicitly contraindicated in the provided studies.
  • However, it is essential to note that patients with erectile dysfunction may have underlying cardiovascular conditions, and the use of tadalafil with other medications, including beta blockers, should be carefully evaluated on a case-by-case basis 3, 5.

Hemodynamic Effects

  • Tadalafil has been shown to have a mild effect on blood pressure, with a reduction in blood pressure that is generally not of clinical concern 3, 5.
  • The additive effect of tadalafil with one or multiple antihypertensive drugs, including beta blockers, is modest 4, 5.
  • The incidence of cardiovascular events, including hypotension and syncope, is comparable between patients taking tadalafil and those taking placebo, even in patients receiving concomitant antihypertensive therapy 5.

Drug-Drug Interactions

  • The use of tadalafil with other medications, including beta blockers, should be carefully evaluated due to the potential for drug-drug interactions 6.
  • Precaution is suggested when using tadalafil with potent CYP3A inhibitors, such as azole antifungals, antiretroviral protease inhibitors, or macrolid antibiotics, as tadalafil is metabolized mainly via the CYP3A4 pathway 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Cardiovascular effects of phosphodiesterase 5 inhibitors.

Current pharmaceutical design, 2006

Research

The cardiovascular safety of tadalafil.

Expert opinion on drug safety, 2008

Research

Phosphodiesterase-5 inhibitors and their hemodynamic effects.

Current hypertension reports, 2006

Research

The use of phosphodiesterase 5 inhibitors with concomitant medications.

Journal of endocrinological investigation, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.